Nanogen Issued Patent for Enhancing Molecular Biological Reactions

    SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN),
 developer of molecular and point-of-care diagnostic products, announced today
 that it was issued U.S. Patent No. 6,780,584, "Electronic Systems and
 Component Devices for Macroscopic and Microscopic Molecular Biological
 Reactions, Analyses and Diagnostics," by the U.S. Patent and Trademark Office.
 The '584 patent covers the design, development, and capability of an
 electronic system to carry out and control multi-step and multiplex reactions
 in macroscopic or microscopic formats.  The system described in the patent is
 at the core of Nanogen's electronic microarray technology, which uses
 electricity to move and concentrate biological samples in miniature formats
 for diagnostic applications.
     The '584 patent covers technology that controls biological reactions by
 managing the localized concentration of two or more reaction-dependant
 molecules and their reaction environment.  This approach greatly enhances the
 rate and specificity of the molecular biological reaction, as evidenced by the
 Nanogen microarray's ability to accelerate molecular binding up to 1,000 times
 faster than traditional passive methods.  The technology described in this
 broad patent enables control over a wide range of molecular reactions involved
 in molecular analyses and diagnostics, including nucleic acid hybridizations
 and amplification, antibody and antigen reactions, and more.
     "Nanogen's unique approach of integrating sophisticated microelectronics
 and molecular biology made the NanoChip(R) Electronic Microarray the first to
 be used in developing fast and accurate molecular diagnostic tests," said
 Howard C. Birndorf, Nanogen chairman and chief executive officer.  "With the
 issuance of patent '584, Nanogen increases its intellectual property portfolio
 enabling the continued development and commercialization of advanced
 diagnostics that provide physicians and patients valuable healthcare
 information."
 
     About Nanogen
     Nanogen, Inc. develops and commercializes products for the molecular and
 point-of-care diagnostics markets.  The company seeks to establish the unique,
 open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R)
 Cartridge as the standard platform for the prediction, diagnosis and treatment
 of genetic and infectious diseases.  Nanogen offers Analyte Specific Reagents
 and related products to research and clinical reference labs for the
 development of tests for the detection of genetic mutations associated with a
 variety of diseases, such as cystic fibrosis, Alzheimer's disease, and
 cardiovascular disease.  The company's ten years of research involving
 nanotechnology may also have future applications in medical diagnostics,
 biowarfare and other industries.  Nanogen's business unit, SynX Pharma,
 leverages proteomic and biomarker research to offer a line of point-of-care
 diagnostic tests.  For additional information please visit Nanogen's website
 at www.nanogen.com.
 
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 Nanogen's NanoChip(R) System can be successfully further commercialized,
 whether other products under development can be successfully developed and
 commercialized, whether results reported by our customers or partners can be
 identically replicated, whether ASRs currently sold by Nanogen will become
 FDA-approved molecular diagnostic test kits, whether Nanogen will be
 successful in developing additional ASRs and protocols utilizing the
 NanoChip(R) System, and other risks and uncertainties discussed under the
 caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K
 for the year ended December 31, 2003 filed with the Securities and Exchange
 Commission.  These forward-looking statements speak only as of the date
 hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.
 
 

SOURCE Nanogen, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.